Recommended
OUR SERVICE
In all critical stages in the drug life cycle, BaiPharm can provide specific recommendations
and actionable solutions to clients.
VIEW MORE >
Consulting of current regulation and policy

NMPA related application for clinical trial and marketing approval

Compliance support from product development to commercialization

Post-market drug safety and risk management

Latest News

POLICY
China Emphasizes Rare Disease & Pediatric Drugs in Adjusting the 2022 National Reimbursement Drug List (NRDL)
On June 29, 2022, China NHSA issued the Work Plan for Adjusting the 2022 National Reimbursement Drug List (NRDL). NRDL is a list of drugs covered by the basic national insurance for healthcare, employment injury, and maternity.
Jul 04, 2022

REGULATION
China Implements GMP Appendix for Investigational Products Used in Clinical Trials
On July 1, 2022, the Appendix to GMP for Pharmaceuticals: Investigational Products Used in Clinical Trials comes into effect. The Appendix is a supporting document for China's pharmaceutical GMP, which was revised in 2010 and has been effective since 2011.
Jul 01, 2022

REGULATION
European Commission Publishes Draft on Labeling Requirements for IMPs
With the application of the EU Clinical Trials Regulation some labelling requirements for IMPs have changed, in particular regarding the expiry date. Now an initiative eliminates the obligation to include an expiry date on the immediate packaging of IMPs in specific circumstances.
Jun 22, 2022

REGULATION
EMA Issues New Guidance Documents for GCP Inspections
Following the previously published list of documents needed during GCP inspections, the EMA issued a set of updated documents on planning and conducting GCP inspections on its website. The annexes compile specific items that may be verified at the sponsor / CRO / investigator site and clinical laboratories.
Jun 22, 2022